Jeff Settleman

27.6k total citations · 8 hit papers
66 papers, 20.5k citations indexed

About

Jeff Settleman is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeff Settleman has authored 66 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 31 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeff Settleman's work include Lung Cancer Treatments and Mutations (19 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and HER2/EGFR in Cancer Research (10 papers). Jeff Settleman is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), PI3K/AKT/mTOR signaling in cancer (11 papers) and HER2/EGFR in Cancer Research (10 papers). Jeff Settleman collaborates with scholars based in United States, France and Canada. Jeff Settleman's co-authors include Anurag Singh, Daniel A. Haber, Raffaella Sordella, Daphne W. Bell, Brian W. Brannigan, Ross A. Okimoto, Sara M. Haserlat, Patricia L. Harris, Thomas J. Lynch and David C. Christiani and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Jeff Settleman

65 papers receiving 20.1k citations

Hit Papers

Activating Mutations in the Epidermal Growth Factor Recep... 2004 2026 2011 2018 2004 2010 2010 2012 2009 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
    2004 8.9k citations Daphne W. Bell, Raffaella Sordella et al. profile →
  2. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
    2010 2.1k citations Anurag Singh, Jeff Settleman profile →
  3. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
    2010 1.8k citations Sreenath V. Sharma, Diana Lee et al. Cell profile →
  4. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
    2012 884 citations Timothy R. Wilson, Emily Chan et al. profile →
  5. A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
    2009 630 citations Anurag Singh, Patricia Greninger et al. Cancer Cell profile →
  6. Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism
    2015 615 citations Jeff Settleman, Sridhar Ramaswamy et al. profile →
  7. Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
    2014 438 citations Ho-June Lee, Guanglei Zhuang et al. Cancer Cell profile →
  8. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    2012 367 citations Jeff Settleman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Settleman United States 38 10.8k 10.6k 8.5k 5.1k 1.5k 66 20.5k
Titus J. Boggon United States 46 8.5k 0.8× 9.6k 0.9× 8.9k 1.0× 3.7k 0.7× 1.1k 0.8× 128 19.1k
Kazuto Nishio Japan 69 8.0k 0.7× 7.6k 0.7× 6.2k 0.7× 3.5k 0.7× 1.5k 1.0× 532 16.2k
Nicola Normanno Italy 63 10.5k 1.0× 8.4k 0.8× 5.6k 0.7× 4.5k 0.9× 2.2k 1.5× 362 18.5k
Geoffrey I. Shapiro United States 79 12.8k 1.2× 12.9k 1.2× 7.8k 0.9× 3.0k 0.6× 1.9k 1.3× 500 23.0k
Nicholas C. Turner United Kingdom 69 14.8k 1.4× 11.9k 1.1× 11.2k 1.3× 9.3k 1.8× 2.1k 1.4× 348 26.7k
Hiroyuki Mano Japan 66 8.4k 0.8× 9.4k 0.9× 8.5k 1.0× 4.6k 0.9× 2.1k 1.4× 262 19.5k
Sabina Signoretti United States 69 6.9k 0.6× 11.5k 1.1× 8.2k 1.0× 6.2k 1.2× 1.2k 0.8× 296 20.4k
Mario Campone France 66 15.3k 1.4× 7.6k 0.7× 9.0k 1.1× 7.1k 1.4× 1.2k 0.8× 538 23.9k
John A. Foekens Netherlands 79 11.4k 1.1× 13.5k 1.3× 3.6k 0.4× 10.6k 2.1× 1.5k 1.0× 337 25.5k
Frank G. Haluska United States 51 10.9k 1.0× 7.9k 0.7× 8.0k 0.9× 3.0k 0.6× 1.4k 1.0× 138 18.7k

Countries citing papers authored by Jeff Settleman

Since Specialization
Citations

This map shows the geographic impact of Jeff Settleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Settleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Settleman more than expected).

Fields of papers citing papers by Jeff Settleman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Settleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Settleman. The network helps show where Jeff Settleman may publish in the future.

Co-authorship network of co-authors of Jeff Settleman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Settleman. A scholar is included among the top collaborators of Jeff Settleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Settleman. Jeff Settleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gandhi, T. K. B., Ellen P.S. Man, John G. Clohessy, et al.. (2020). Targeting microtubule sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors. Theranostics. 10(6). 2727–2743. 7 indexed citations
2.
Wang, Victoria E., Jenny Y. Xue, Dennie T. Frederick, et al.. (2019). Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clinical Cancer Research. 25(23). 7202–7217. 37 indexed citations
3.
Sahu, Nisebita, Emily Chan, Felix Chu, et al.. (2017). Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(9). 1729–1738. 26 indexed citations
4.
Lee, Ho-June, Yi Cao, Victoria C. Pham, et al.. (2017). Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Molecular Cancer Therapeutics. 16(4). 694–704. 16 indexed citations
5.
Liu, Qi, Meng Wang, Jing Han, et al.. (2015). Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research. 13(4). 713–720. 29 indexed citations
6.
Wilson, Catherine, Xiaofen Ye, Eva Lin, et al.. (2014). AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs. Cancer Research. 74(20). 5878–5890. 116 indexed citations
7.
Wang, Meng, Patricia Greninger, Anurag Singh, et al.. (2014). EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research. 74(10). 2825–2834. 55 indexed citations
8.
Raha, Debasish, Timothy R. Wilson, Jing Peng, et al.. (2014). The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Research. 74(13). 3579–3590. 223 indexed citations
9.
Sun, Yuting, Anneleen Daemen, Georgia Hatzivassiliou, et al.. (2014). Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer & Metabolism. 2(1). 20–20. 98 indexed citations
10.
Lee, Ho-June, Guanglei Zhuang, Yi Cao, et al.. (2014). Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. Cancer Cell. 26(2). 207–221. 438 indexed citations breakdown →
11.
12.
Lee, Ho‐June, Gabriele Schaefer, Timothy P. Heffron, et al.. (2012). Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M. Cancer Discovery. 3(2). 168–181. 68 indexed citations
13.
Singh, Anurag, Michael F. Sweeney, Min Yu, et al.. (2012). TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers. Cell. 148(4). 639–650. 222 indexed citations
14.
Wilson, Timothy R., Diana Lee, Leanne Berry, David S. Shames, & Jeff Settleman. (2011). Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers. Cancer Cell. 20(2). 158–172. 125 indexed citations
15.
Sharma, Sreenath V., Diana Lee, Bihua Li, et al.. (2010). A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell. 141(1). 69–80. 1828 indexed citations breakdown →
16.
McDermott, Ultan, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, & Jeff Settleman. (2010). Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency. Cancer Research. 70(4). 1625–1634. 129 indexed citations
17.
Contreras, Cristina M., Esra A. Akbay, Teresa D. Gallardo, et al.. (2010). Lkb1inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Disease Models & Mechanisms. 3(3-4). 181–193. 92 indexed citations
18.
Galimberti, Fabrizio, Xi Liu, Hua Li, et al.. (2009). Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe. Clinical Cancer Research. 16(1). 109–120. 60 indexed citations
19.
Jänne, Pasi A., Nathanael S. Gray, & Jeff Settleman. (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Reviews Drug Discovery. 8(9). 709–723. 242 indexed citations
20.
Bell, Daphne W., Ira Gore, Ross A. Okimoto, et al.. (2005). Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics. 37(12). 1315–1316. 380 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Titus J. Boggon Breakdown of academic impact, for papers by Kazuto Nishio Breakdown of academic impact, for papers by Nicola Normanno Breakdown of academic impact, for papers by Geoffrey I. Shapiro Breakdown of academic impact, for papers by Nicholas C. Turner Breakdown of academic impact, for papers by Hiroyuki Mano Breakdown of academic impact, for papers by Sabina Signoretti Breakdown of academic impact, for papers by Mario Campone Breakdown of academic impact, for papers by John A. Foekens Breakdown of academic impact, for papers by Frank G. Haluska
Rankless by CCL
2026